{
    "clinical_study": {
        "@rank": "110893", 
        "acronym": "SAIFER", 
        "arm_group": {
            "arm_group_label": "Cohort", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Hemochromatosis type 1 is one of the most frequent genetic disease since the genetic\n      predisposition (homozygosity for the C282Y mutation of the HFE gene) is encountered in about\n      3/1000 white subjects (5/1000 in  Brittany, France).\n\n      For the half of these predisposed subjects, the phenotypic expression of the disease needs a\n      treatment. This treatment is based upon repeated bloodletting which is generally considered\n      as simple, safe and effective.\n\n      Nevertheless, it is still questioned as regard its physiopathological justification and its\n      clinical implications. Indeed, bloodletting could cause an increase of  non-transferrin\n      bound iron (NTBI) particularly for its reactive form called labile plasma iron (LPI) This\n      adverse physiopathological effect could have clinical consequences and could be linked with\n      articular consequences which can be aggravated by the treatment."
        }, 
        "brief_title": "Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hemochromatosis Type 1", 
        "condition_browse": {
            "mesh_term": "Hemochromatosis"
        }, 
        "detailed_description": {
            "textblock": "Hemochromatosis type 1 is one of the most frequent genetic disease since the genetic\n      predisposition (homozygosity for the C282Y mutation of the HFE gene) is encountered in about\n      3/1000 white subjects (5/1000 in Brittany, France).\n\n      For the half of these predisposed subjects, the phenotypic expression of the disease needs a\n      treatment. This treatment is based upon repeated bloodletting which is generally considered\n      as simple, safe and effective.\n\n      Nevertheless, it is still questioned as regard its physiopathological justification and its\n      clinical implications. Indeed, bloodletting could cause an increase of  non-transferrin\n      bound iron (NTBI) particularly for its reactive form called labile plasma iron (LPI) This\n      adverse physiopathological effect could have clinical consequences and could be linked with\n      articular consequences which can be aggravated by the treatment.\n\n      The primary objective is to explore the effect of bloodletting upon plasmatic concentrations\n      of NTBI.\n\n      The secondary objectives are to:\n\n        -  explore the impact of bloodletting upon different parameters of iron metabolism and in\n           particular LPI, hepcidinemia and markers of erythropoiesis ;\n\n        -  explore basal and nycthemeral characteristics of new parameters of iron metabolism\n           (hepcidin, NTBI, LPI) in hemochromatosic patients.\n\n      The demonstration of an adverse effect of bloodletting upon iron metabolism would allow for\n      a therapeutic innovation based upon an association of bloodletting and oral chelation during\n      the induction treatment of type 1 hemochromatosis and, more generally in hepcidino deficient\n      forms of hemochromatosis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men\n\n          -  Aged between 18 and 65\n\n          -  Homozygosity for the C282Y mutation of the HFE gene\n\n          -  With an indication of treatment by bloodletting (in accordance with the French HAS\n             guidelines)\n\n          -  Ferritinemia \u2265 500\u00b5g/L\n\n          -  Transferrin saturation \u2265 75%\n\n          -  Never treated by bloodletting\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Contraindication to bloodletting\n\n          -  Chronic inflammatory or dysmetabolic or neoplastic disease\n\n          -  Major cardiovascular disease\n\n          -  Excessive consumption of alcohol (\u2265 3gr/day)\n\n          -  Treatment by iron chelators, C or E vitamins\n\n          -  Active tabagism or tabagism stopped from less than 6 months\n\n          -  Stay in altitude> 1500m in the month preceding the period Day 1\n\n          -  Patients under guardianship\n\n          -  Blood donation in the 3 past months\n\n          -  Night / shift workers"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01810965", 
            "org_study_id": "ANSM 2012-A01392-41"
        }, 
        "intervention": {
            "arm_group_label": "Cohort", 
            "intervention_name": "First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Hemochromatosis type 1", 
        "lastchanged_date": "December 24, 2013", 
        "location": {
            "contact": {
                "email": "martine.ropert@chu-rennes.fr", 
                "last_name": "Martine Ropert-Bouchet, MD", 
                "phone": "(0) 2.99.28.42.75", 
                "phone_ext": "+ 33"
            }, 
            "facility": {
                "address": {
                    "city": "Rennes", 
                    "country": "France", 
                    "zip": "35000"
                }, 
                "name": "CHU Pontchaillou"
            }, 
            "investigator": {
                "last_name": "Martine Ropert-Bouchet, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis: Pathophysiological and Clinical Implications. Pilot Study.", 
        "overall_contact": {
            "email": "martine.ropert@chu-rennes.fr", 
            "last_name": "Martine Ropert-Bouchet, MD", 
            "phone": "02.99.28.42.75"
        }, 
        "overall_official": [
            {
                "affiliation": "Rennes University Hospital", 
                "last_name": "Martine Ropert-Bouchet, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Rennes University Hospital", 
                "last_name": "Bruno Laviolle, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximal variation (delta maximum) of NTBI during the 5 days following a bloodletting", 
            "safety_issue": "No", 
            "time_frame": "Day 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01810965"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Kinetic of NTBI plasmatic concentration during the 5 days following a bloodletting", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "measure": "Maximal variation (delta maximum) of LPI during the 5 days following a bloodletting", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "measure": "Maximal variation (delta maximum) of hepcidin during the 5 days following a bloodletting", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "measure": "Kinetic of LPI plasmatic concentration during the 5 days following a bloodletting", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "measure": "Kinetic of hepcidin plasmatic concentration during the 5 days following a bloodletting", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "measure": "CRP", 
                "safety_issue": "No", 
                "time_frame": "Day 9, day 10, day 11 and day 12"
            }, 
            {
                "measure": "Hemoglobin", 
                "safety_issue": "No", 
                "time_frame": "Day 9, day 10, day 11 and day 12"
            }, 
            {
                "measure": "Soluble transferrin receptor", 
                "safety_issue": "No", 
                "time_frame": "Day 9, day 10, day 11 and day 12"
            }, 
            {
                "measure": "EPO", 
                "safety_issue": "No", 
                "time_frame": "Day 9, day 10, day 11 and day 12"
            }, 
            {
                "measure": "Circadian kinetic of NTBI plasmatic concentration when no bloodletting is performed", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Circadian kinetic of API plasmatic concentration when no bloodletting is performed", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Circadian kinetic of hepcidine plasmatic concentration when no bloodletting is performed", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "measure": "Maximal variation (delta maximum) of transferrin saturation during the 5 days following a bloodletting", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "measure": "Kinetic of transferrin saturation during the 5 days following a bloodletting", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }
        ], 
        "source": "Rennes University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rennes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}